ReviewPharmaceuticals (Basel, Switzerland)2020
Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer's Disease.
Review in Pharmaceuticals (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 49 citations in OpenAlex.
- Functional Implications of Marine Biosurfactants and Their Therapeutic Potential Against Alzheimer's Disease.Food science & nutrition · 2026Review
- Synthesis and Biological Profiling of New 1,2,3,4-Tetrahydrobenzo[Biomolecules · 2026Article
- Exploring the Biological Potency of Carotenoids Against Alzheimer's Disease: An Integrated Approach of Molecular Docking and Molecular Dynamics.Current issues in molecular biology · 2026Article
- Solid lipid nanoparticles as carriers forFrontiers in aging neuroscience · 2026Article
- Vitamin D and omega-3 fatty acids attenuate MSG-induced neurodegeneration by modulating tau pathology, neuroinflammation, and VDR expression in rats.Scientific reports · 2025Article
- Natural products in neurodegenerative diseases: recent advances and future outlook.Frontiers in pharmacology · 2025Review
- Anticholinesterase and Anti-Inflammatory Activities of the Essential Oils of Sawdust and Resin-Rich Bark from AzoreanInternational journal of molecular sciences · 2024Article
- Seaweeds as Nutraceutical Elements and Drugs for Diabetes Mellitus: Future Perspectives.Marine drugs · 2024Review
- Potential of Tryptamine Derivatives as Multi-Target Directed Ligands for Alzheimer's Disease: AChE, MAO-B, and COX-2 as Molecular Targets.Molecules (Basel, Switzerland) · 2024Article
- Marine-derived Compounds: A Powerful Platform for the Treatment of Alzheimer's Disease.Central nervous system agents in medicinal chemistry · 2024Review
- Neuroprotective Effects of N-methyl-(2S, 4R)-trans-4-hydroxy-L-proline (NMP) against Amyloid-β-Induced Alzheimer's Disease Mouse Model.Nutrients · 2023Article
- Review
- Marine Sources of DHA-Rich Phospholipids with Anti-Alzheimer Effect.Marine drugs · 2022Review
- Investigating the structure-activity relationship of marine polycyclic batzelladine alkaloids as promising inhibitors for SARS-CoV-2 main protease (MComputers in biology and medicine · 2022Article
- Fiscalin Derivatives as Potential Neuroprotective Agents.Pharmaceutics · 2022Article
- Unveiling the Multitarget Anti-Alzheimer Drug Discovery Landscape: A Bibliometric Analysis.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Paeonol Ameliorates Cognitive Deficits in Streptozotocin Murine Model of Sporadic Alzheimer's Disease via Attenuation of Oxidative Stress, Inflammation, and Mitochondrial Dysfunction.Journal of molecular neuroscience : MN · 2022Article
- Review
- Natural product-based pharmacological studies for neurological disorders.Frontiers in pharmacology · 2022Review
- Editorial: Experimental and Innovative Approaches to Multi-Target Treatment of Parkinson's and Alzheimer's Diseases.Frontiers in neuroscience · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Alzheimer's disease (AD) is a multifactorial disease characterized by the presence of amyloid plaques, neurofibrillary tangles, and nerve cell death that affects, mainly, older people. After decades of investigation, the search for an efficacious treatment for AD remains and several strategies can be and are being employed in this journey. In this review, four of the most promising strategies, alongside with its most promising agents under investigation or development are highlighted. Marine natural products (MNP) are a source of unique chemical structures with useful biological activities for AD treatment. One of the most promising compounds, a marine-derived acidic oligosaccharide (GV-971) just passed phase III clinical trials with a unique mechanism of action. Combination therapy and multitargeted-directed ligand therapy (MTDL) are also two important strategies, with several examples in clinical trials, based on the belief that the best approach for AD is a therapy capable of modulating multiple target pathways. Drug repurposing, a strategy that requires a smaller investment and is less time consuming, is emerging as a strong contender with a variety of pharmacological agents resurfacing in an attempt to identify a therapeutic candidate capable of modifying the course of this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.